Abstract
FDA has approved the marketing of methylnaltrexone bromide subcutaneous injection for the treatment of opioid-induced constipation in adults receiving palliative care for advanced illness. The product is sold by Wyeth Pharmaceuticals under the brand name Relistor. FDA-approved labeling for
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
